GE Healthcare announced that its FASTlab synthesizer combined with solid-phase extraction and the application of chemometric tools can increase the reliability of the manufacturing and synthesis of F-18 flutemetamol, according to data presented in scientific abstracts.
The abstracts were presented at the European Association of Nuclear Medicine (EANM) annual congress, held 15-19 October in Birmingham, U.K. F-18 flutemetamol is a GE PET investigational imaging agent currently in phase III development for detecting beta amyloid using PET brain scans.
Data from the technical research abstracts suggest that use of the automated GE FASTlab synthesizer and cassette-based solid-phase extraction in place of preparative high-performance liquid chromatography for purifying F-18 flutemetamol reduces presynthesis preparation time and may reduce the scope of operator error, according to the company.
